{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:23:08Z","timestamp":1792002188660,"version":"4.4.0"},"reference-count":214,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Psoriasis is an immune-mediated disease with a strong genetic component that brings many challenges to sick individuals, such as chronic illness, and which has multiple associated comorbidities like cardiovascular disease, metabolic syndrome, inflammatory bowel disease, and psychological disorders. Understanding the interplay between the innate and adaptative immune system has led to the discovery of specific cytokine circuits (Tumor Necrosis Factor-alpha (TNF-\u03b1), IL-23, IL-17), which has allowed scientists to discover new biomarkers that can be used as predictors of treatment response and pave the way for personalized treatments. In this review, we describe the footprint psoriasis leaves on the skin and beyond, key pathophysiological mechanisms, current available therapeutic options, and drawbacks faced by existing therapies, and we anticipate potential future perspectives that may improve the quality of life of affected individuals.<\/jats:p>","DOI":"10.3390\/ijms242216095","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T03:42:08Z","timestamp":1699501328000},"page":"16095","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["Inflammation and Psoriasis: A Comprehensive Review"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6273-0787","authenticated-orcid":false,"given":"Alessandra-M\u0103d\u0103lina","family":"Man","sequence":"first","affiliation":[{"name":"Physiology Department, Faculty of Medicine, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400126 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meda Sandra","family":"Or\u0103san","sequence":"additional","affiliation":[{"name":"Physiopathology Department, Faculty of Medicine, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400126 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana-Alina","family":"Hoteiuc","sequence":"additional","affiliation":[{"name":"Physiology Department, Faculty of Medicine, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400126 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Cristina","family":"Ol\u0103nescu-Vaida-Voevod","sequence":"additional","affiliation":[{"name":"Physiology Department, Faculty of Medicine, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400126 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Mocan","sequence":"additional","affiliation":[{"name":"Physiology Department, Faculty of Medicine, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400126 Cluj-Napoca, Romania"},{"name":"Nanomedicine Department, Regional Institute of Gastroenterology and Hepatology, 400158 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.5114\/ada.2020.94832","article-title":"Pathogenesis of Psoriasis in the \u201cOmic\u201d Era. Part I. Epidemiology, Clinical Manifestation, Immunological and Neuroendocrine Disturbances","volume":"37","author":"Samotij","year":"2020","journal-title":"Postep. Dermatol. Allergol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis Causes as Much Disability as Other Major Medical Diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, Regional, and Worldwide Epidemiology of Psoriasis: Systematic Analysis and Modelling Study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/bjd.19169","article-title":"Systematic Review Examining Changes over Time and Variation in the Incidence and Prevalence of Psoriasis by Age and Gender","volume":"184","author":"Iskandar","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"H\u00e4gg, D., Eriksson, M., Sundstr\u00f6m, A., and Schmitt-Egenolf, M. (2013). The Higher Proportion of Men with Psoriasis Treated with Biologics May Be Explained by More Severe Disease in Men. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0063619"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"adv00030","DOI":"10.2340\/00015555-3384","article-title":"Psoriasis and Genetics","volume":"100","author":"Dand","year":"2020","journal-title":"Acta Derm.-Venereol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.molimm.2014.12.014","article-title":"Genetic and Epigenetic Basis of Psoriasis Pathogenesis","volume":"64","author":"Chandra","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"15382","DOI":"10.1038\/ncomms15382","article-title":"Large Scale Meta-Analysis Characterizes Genetic Architecture for Common Psoriasis Associated Variants","volume":"8","author":"Tsoi","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2, Strange, A., Capon, F., Spencer, C.C.A., Knight, J., Weale, M.E., Allen, M.H., Barton, A., Band, G., and Bellenguez, C. (2010). A Genome-Wide Association Study Identifies New Psoriasis Susceptibility Loci and an Interaction between HLA-C and ERAP1. Nat. Genet., 42, 985\u2013990.","DOI":"10.1038\/ng.694"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.jaci.2018.11.038","article-title":"HLA-C*06:02 Genotype Is a Predictive Biomarker of Biologic Treatment Response in Psoriasis","volume":"143","author":"Dand","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Burlando, M., Russo, R., Clapasson, A., Carmisciano, L., Stecca, A., Cozzani, E., and Parodi, A. (2020). The HLA-Cw6 Dilemma: Is It Really an Outcome Predictor in Psoriasis Patients under Biologic Therapy? A Monocentric Retrospective Analysis. J. Clin. Med., 9.","DOI":"10.3390\/jcm9103140"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/bjd.16705","article-title":"Secukinumab Shows High Efficacy Irrespective of HLA-Cw6 Status in Patients with Moderate-to-Severe Plaque-Type Psoriasis: SUPREME Study","volume":"179","author":"Costanzo","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1046\/j.0022-202x.2001.01656.x","article-title":"HLA-Cw6-Positive and HLA-Cw6-Negative Patients with Psoriasis Vulgaris have Distinct Clinical Features","volume":"118","author":"Gulcher","year":"2002","journal-title":"J. Investig. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/exd.14709","article-title":"Characteristics and Pathogenesis of Koebner Phenomenon","volume":"32","author":"Zhang","year":"2023","journal-title":"Exp. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5114\/reum.2022.120752","article-title":"The Role of HLA-Cw6 in Psoriasis and Psoriatic Arthritis","volume":"60","author":"Owczarek","year":"2022","journal-title":"Rheumatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"740968","DOI":"10.3389\/fimmu.2021.740968","article-title":"Predicting the Risk of Psoriatic Arthritis in Plaque Psoriasis Patients: Development and Assessment of a New Predictive Nomogram","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/art.24172","article-title":"Incidence and Clinical Predictors of Psoriatic Arthritis in Patients with Psoriasis: A Population-Based Study","volume":"61","author":"Wilson","year":"2009","journal-title":"Arthritis Care Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1046\/j.1365-2133.2000.03885.x","article-title":"HLA-C and Guttate Psoriasis","volume":"143","author":"Mallon","year":"2000","journal-title":"Br. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"adv00034","DOI":"10.2340\/00015555-3388","article-title":"Pustular Psoriasis: The Dawn of a New Era","volume":"100","author":"Bachelez","year":"2020","journal-title":"Acta Derm.-Venereol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ajhg.2011.07.022","article-title":"Mutations in IL36RN\/IL1F5 Are Associated with the Severe Episodic Inflammatory Skin Disease Known as Generalized Pustular Psoriasis","volume":"89","author":"Onoufriadis","year":"2011","journal-title":"Am. J. Hum. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaci.2018.06.038","article-title":"Clinical and Genetic Differences between Pustular Psoriasis Subtypes","volume":"143","author":"Twelves","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.3389\/fimmu.2018.01323","article-title":"The Interleukin-23\/Interleukin-17 Axis Links Adaptive and Innate Immunity in Psoriasis","volume":"9","author":"Erpenbeck","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1038\/jid.2015.186","article-title":"Palmoplantar Pustular Psoriasis Is Associated with Missense Variants in CARD14, but Not with Loss-of-Function Mutations in IL36RN in European Patients","volume":"135","author":"Frambach","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","article-title":"Psoriasis: A brief overview","volume":"21","author":"Raharja","year":"2021","journal-title":"Clin. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Dopytalska, K., Ciechanowicz, P., Wiszniewski, K., Szyma\u0144ska, E., and Walecka, I. (2021). The Role of Epigenetic Factors in Psoriasis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179294"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1245876","DOI":"10.3389\/fimmu.2023.1245876","article-title":"DNA Methylation Patterns in CD4+ T-Cells Separate Psoriasis Patients from Healthy Controls, and Skin Psoriasis from Psoriatic Arthritis","volume":"14","author":"Natoli","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/exd.14332","article-title":"Dysregulated Epigenetic Modifications in Psoriasis","volume":"30","author":"Zeng","year":"2021","journal-title":"Exp. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/exd.13790","article-title":"Histone Modifications Associated with Biological Drug Response in Moderate-to-Severe Psoriasis","volume":"27","author":"Reolid","year":"2018","journal-title":"Exp. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Domingo, S., Sol\u00e9, C., Molin\u00e9, T., Ferrer, B., and Cort\u00e9s-Hern\u00e1ndez, J. (2020). MicroRNAs in Several Cutaneous Autoimmune Diseases: Psoriasis, Cutaneous Lupus Erythematosus and Atopic Dermatitis. Cells, 9.","DOI":"10.3390\/cells9122656"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.4049\/jimmunol.2100686","article-title":"ERAP1 Controls the Autoimmune Response against Melanocytes in Psoriasis by Generating the Melanocyte Autoantigen and Regulating Its Amount for HLA-C*06:02 Presentation","volume":"207","author":"Arakawa","year":"2021","journal-title":"J. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fimmu.2018.00080","article-title":"RNA-Seq Analysis of IL-1B and IL-36 Responses in Epidermal Keratinocytes Identifies a Shared MyD88-Dependent Gene Signature","volume":"9","author":"Swindell","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2353\/ajpath.2008.070710","article-title":"Revisiting the Koebner Phenomenon: Role of NGF and Its Receptor System in the Pathogenesis of Psoriasis","volume":"172","author":"Raychaudhuri","year":"2008","journal-title":"Am. J. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"652191","DOI":"10.3389\/fimmu.2021.652191","article-title":"Resident Memory T Cells in Autoimmune Skin Diseases","volume":"12","author":"Ryan","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3389\/fimmu.2019.01440","article-title":"Type1 Interferons Potential Initiating Factors Linking Skin Wounds with Psoriasis Pathogenesis","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/sj.jid.5700104","article-title":"Neuroimmunology of Stress: Skin Takes Center Stage","volume":"126","author":"Arck","year":"2006","journal-title":"J. Investig. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Martins, A.M., Ascenso, A., Ribeiro, H.M., and Marto, J. (2020). The Brain\u2013Skin Connection and the Pathogenesis of Psoriasis: A Review with a Focus on the Serotonergic System. Cells, 9.","DOI":"10.3390\/cells9040796"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Zhou, S., and Yao, Z. (2022). Roles of Infection in Psoriasis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23136955"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1399-0039.1998.tb03083.x","article-title":"Staphylococcal Enterotoxin-A Directly Stimulates Signal Transduction and Interferon-\u03b3 production in Psoriatic T-Cell Lines","volume":"52","author":"Nielsen","year":"1998","journal-title":"Tissue Antigens"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S1473-3099(10)70101-8","article-title":"HIV-Associated Psoriasis: Pathogenesis, Clinical Features, and Management","volume":"10","author":"Morar","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5070\/D34SF63339","article-title":"Unraveling the Paradoxes of HIV-Associated Psoriasis: A Review of T-Cell Subsets and Cytokine Profiles","volume":"13","author":"Fife","year":"2007","journal-title":"Dermatol. Online J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/0956462419827673","article-title":"Psoriasis in HIV Infection: An Update","volume":"30","author":"Filipe","year":"2019","journal-title":"Int. J. STD AIDS"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3892\/etm.2021.9999","article-title":"Infection-Provoked Psoriasis: Induced or Aggravated (Review)","volume":"21","author":"Teng","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1080\/17512433.2019.1665027","article-title":"A Review of Antibiotics and Psoriasis: Induction, Exacerbation, and Amelioration","volume":"12","author":"Tsai","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Polak, K., Bergler-Czop, B., Szczepanek, M., Wojciechowska, K., Fr\u0105tczak, A., and Kiss, N. (2021). Psoriasis and Gut Microbiome\u2014Current State of Art. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094529"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/jamadermatol.2014.5585","article-title":"Identification of Bacterial DNA in the Peripheral Blood of Patients with Active Psoriasis","volume":"151","author":"Such","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00128071-200102030-00005","article-title":"Psoriasis of the Scalp. Diagnosis and Management","volume":"2","author":"Franssen","year":"2001","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/j.1468-3083.2007.02424.x","article-title":"Scalp Psoriasis: A Review of Current Topical Treatment Options","volume":"21","author":"Papp","year":"2007","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1468-3083.2009.03364.x","article-title":"Approach to Managing Patients with Nail Psoriasis","volume":"23","author":"Reich","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2005.07.073","article-title":"Psoriasis of the Nail: Anatomy, Pathology, Clinical Presentation, and a Review of the Literature on Therapy","volume":"57","author":"Jiaravuthisan","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.autrev.2014.01.008","article-title":"Diagnosis and Classification of Psoriasis","volume":"13","author":"Raychaudhuri","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.clindermatol.2007.08.005","article-title":"The Histopathologic Spectrum of Psoriasis","volume":"25","author":"Murphy","year":"2007","journal-title":"Clin. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/jocd.14086","article-title":"The Significance of Endocan Immunohistochemical Expression in Chronic Plaque Psoriasis","volume":"21","author":"Abdou","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2133.2004.06168.x","article-title":"Perforin Expression Is Upregulated in the Epidermis of Psoriatic Lesions","volume":"151","author":"Kastelan","year":"2004","journal-title":"Br. J. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/039463200601900405","article-title":"VEGF is Likely a Key Factor in the Link between Inflammation and Angiogenesis in Psoriasis: Results of an Immunohistochemical Study","volume":"19","author":"Simonetti","year":"2006","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1080\/15321819.2020.1741385","article-title":"Plexin-B2 in Psoriasis; a Clinical and Immunohistochemical Study","volume":"41","author":"Hemida","year":"2020","journal-title":"J. Immunoass. Immunochem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jid.2017.09.005","article-title":"CD100\u2013Plexin-B2 Promotes the Inflammation in Psoriasis by Activating NF-\u03baB and the Inflammasome in Keratinocytes","volume":"138","author":"Zhang","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/bjd.15703","article-title":"Smad7 Positively Regulates Keratinocyte Proliferation in Psoriasis","volume":"177","author":"Laudisi","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1111\/ced.13720","article-title":"Overexpressed Fibulin-3 Contributes to the Pathogenesis of Psoriasis by Promoting Angiogenesis","volume":"44","author":"Wang","year":"2019","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1111\/jocd.13425","article-title":"Smad7 in Psoriasis Vulgaris Patients: A Clinical and Immunohistochemical Study","volume":"19","author":"Hemida","year":"2020","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/10520295.2019.1673901","article-title":"Alteration of Tissue Expression of Human Beta Defensin-1 and Human Beta Defensin-2 in Psoriasis Vulgaris Following Phototherapy","volume":"95","author":"Uzuncakmak","year":"2020","journal-title":"Biotech. Histochem."},{"key":"ref_63","first-page":"EC05","article-title":"Immunohistochemical Evaluation of Role of Serotonin in Pathogenesis of Psoriasis","volume":"10","author":"Younes","year":"2016","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/ijd.12870","article-title":"Advances in Non-Invasive Techniques as Aids to the Diagnosis and Monitoring of Therapeutic Response in Plaque Psoriasis: A Review","volume":"54","author":"Lacarrubba","year":"2015","journal-title":"Int. J. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/jdv.12998","article-title":"A Three-Cohort Comparison with Videodermatoscopic Evidence of the Distinct Homogeneous Bushy Capillary Microvascular Pattern in Psoriasis vs Atopic Dermatitis and Contact Dermatitis","volume":"30","author":"Lacarrubba","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/j.1365-2133.2012.10868.x","article-title":"Accuracy of Dermoscopic Criteria for the Diagnosis of Psoriasis, Dermatitis, Lichen Planus and Pityriasis Rosea","volume":"166","author":"Lallas","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/srt.12933","article-title":"Dermoscopy of Plaque Psoriasis Differs with Plaque Location, Its Duration, and Patient\u2019s Sex","volume":"27","author":"Rudnicka","year":"2021","journal-title":"Ski. Res. Technol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/ijd.13983","article-title":"Clinical and Dermoscopic Response Predictors in Psoriatic Patients Undergoing Narrowband Ultraviolet B Phototherapy: Results from a Prospective Study","volume":"57","author":"Errichetti","year":"2018","journal-title":"Int. J. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5826\/dpc.0604a02","article-title":"Dermoscopic Hemorrhagic Dots: An Early Predictor of Response of Psoriasis to Biologic Agents","volume":"6","author":"Lallas","year":"2016","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/exd.14363","article-title":"High-Frequency Ultrasound as a Scientific Tool for Skin Imaging Analysis","volume":"30","author":"Vergilio","year":"2021","journal-title":"Exp. Dermatol."},{"key":"ref_71","first-page":"4981","article-title":"High-Frequency Ultrasonography of Psoriatic Skin: A Non-Invasive Technique in the Evaluation of the Entire Skin of Patients with Psoriasis: A Pilot Study","volume":"18","author":"Boca","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_72","first-page":"4974","article-title":"Imaging Techniques in the Diagnosis and Monitoring of Psoriasis","volume":"18","author":"Grajdeanu","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.7863\/jum.2009.28.11.1569","article-title":"High-Frequency Sonography in the Evaluation of Psoriasis: Nail and Skin Involvement","volume":"28","author":"Gutierrez","year":"2009","journal-title":"J. Ultrasound Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1111\/j.1529-8019.2009.01267.x","article-title":"Ultrasound Evaluation of Clobetasol Propionate 0.05% Foam Application in Psoriatic and Healthy Skin: A Pilot Study","volume":"22","author":"Lacarrubba","year":"2009","journal-title":"Dermatol. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/ijd.14150","article-title":"Calcipotriol\/Betamethasone Ointment Compared to Narrow-Band UVB in Plaque Psoriasis: First Clinical and Ultrasonographic Study","volume":"58","author":"Gaura","year":"2019","journal-title":"Int. J. Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/srt.12942","article-title":"Ultra-High-Frequency Ultrasound Monitoring of Plaque Psoriasis during Ixekizumab Treatment","volume":"27","author":"Dini","year":"2021","journal-title":"Ski. Res. Technol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1365-2133.2010.10026.x","article-title":"Clinical, Power Doppler Sonography and Histological Assessment of the Psoriatic Plaque: Short-Term Monitoring in Patients Treated with Etanercept","volume":"164","author":"Gutierrez","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/j.1751-1097.2008.00443.x","article-title":"Reflectance Confocal Microscopy for In Vivo Skin Imaging\u2020","volume":"84","author":"Longo","year":"2008","journal-title":"Photochem. Photobiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.det.2012.06.012","article-title":"New Directions in Dermatopathology: In Vivo Confocal Microscopy in Clinical Practice","volume":"30","author":"Longo","year":"2012","journal-title":"Dermatol. Clin."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1468-3083.2009.03134.x","article-title":"Concordance between In Vivo Reflectance Confocal Microscopy and Histology in the Evaluation of Plaque Psoriasis","volume":"23","author":"Ardigo","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1346-8138.2011.01366.x","article-title":"Sensitivity and Specificity of Munro Microabscess Detected by Reflectance Confocal Microscopy in the Diagnosis of Psoriasis Vulgaris","volume":"39","author":"Zhong","year":"2012","journal-title":"J. Dermatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-2133.2012.10988.x","article-title":"Reflectance Confocal Microscopy: An Effective Tool for Monitoring Ultraviolet B Phototherapy in Psoriasis","volume":"167","author":"Wolberink","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1111\/jdv.13235","article-title":"Reflectance Confocal Microscopy for Plaque Psoriasis Therapeutic Follow-up during an Anti-TNF-\u03b1 Monoclonal Antibody: An Observational Multicenter Study","volume":"29","author":"Agozzino","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1034\/j.1600-0846.2000.006001006.x","article-title":"In Vivo Optical Coherence Tomography Imaging of Human Skin: Norm and Pathology","volume":"6","author":"Gladkova","year":"2000","journal-title":"Ski. Res. Technol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00403-003-0390-y","article-title":"Optical Coherence Tomography in Contact Dermatitis and Psoriasis","volume":"295","author":"Welzel","year":"2003","journal-title":"Arch. Dermatol. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/ajd.13695","article-title":"Dermoscopy, Confocal Microscopy and Optical Coherence Tomography Features of Main Inflammatory and Autoimmune Skin Diseases: A Systematic Review","volume":"63","author":"Guida","year":"2022","journal-title":"Australas. J. Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1111\/jdv.18293","article-title":"Line-Field Confocal Optical Coherence Tomography of Psoriasis, Eczema and Lichen Planus: A Case Series with Histopathological Correlation","volume":"36","author":"Broggi","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"995883","DOI":"10.3389\/fmed.2022.995883","article-title":"Case Report: Optical Coherence Tomography for Monitoring Biologic Therapy in Psoriasis and Atopic Dermatitis","volume":"9","author":"Yasak","year":"2022","journal-title":"Front. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00403-009-1000-4","article-title":"Optical Coherence Tomography Imaging of Psoriasis Vulgaris: Correlation with Histology and Disease Severity","volume":"302","author":"Morsy","year":"2010","journal-title":"Arch. Dermatol. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/ced.13786","article-title":"Three-Dimensional Nail Imaging by Optical Coherence Tomography: A Novel Biomarker of Response to Therapy for Nail Disease in Psoriasis and Psoriatic Arthritis","volume":"44","author":"Abignano","year":"2019","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000351702","article-title":"Potential Use of Optical Coherence Tomography and High-Frequency Ultrasound for the Assessment of Nail Disease in Psoriasis and Psoriatic Arthritis","volume":"227","author":"Aydin","year":"2013","journal-title":"Dermatology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.3389\/fimmu.2019.01931","article-title":"Non-invasive Approaches for the Diagnosis of Autoimmune\/Autoinflammatory Skin Diseases\u2014A Focus on Psoriasis and Lupus erythematosus","volume":"10","author":"Tiganescu","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ymeth.2012.10.002","article-title":"Non-Invasive Evaluation of Skin Cytokines Secretion: An Innovative Complementary Method for Monitoring Skin Disorders","volume":"61","author":"Kohen","year":"2013","journal-title":"Methods"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1111\/1346-8138.16032","article-title":"Stratum Corneum Levels of Calprotectin Proteins S100A8\/A9 Correlate with Disease Activity in Psoriasis Patients","volume":"48","author":"Matsunaga","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1072160","DOI":"10.3389\/fmed.2023.1072160","article-title":"Assessment of Soluble Skin Surface Protein Levels for Monitoring Psoriasis Vulgaris in Adult Psoriasis Patients Using Non-Invasive Transdermal Analysis Patch: A Pilot Study","volume":"10","author":"Orro","year":"2023","journal-title":"Front. Med."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Valenzuela, F., Fern\u00e1ndez, J., Jim\u00e9nez, C., Cavagnola, D., Mancilla, J.F., Astorga, J., Hern\u00e1ndez, M., and Fern\u00e1ndez, A. (2021). Identification of IL-18 and Soluble Cell Adhesion Molecules in the Gingival Crevicular Fluid as Novel Biomarkers of Psoriasis. Life, 11.","DOI":"10.3390\/life11101000"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/0300060515598902","article-title":"Salivary Interleukin-1\u03b2: Oral Inflammatory Biomarker in Patients with Psoriasis","volume":"44","author":"Ganzetti","year":"2016","journal-title":"J. Int. Med. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/jdv.14868","article-title":"Shifting the Focus\u2014The Primary Role of IL-23 in Psoriasis and Other Inflammatory Disorders","volume":"32","author":"Gooderham","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 Signaling Pathway and the Treatment of Psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ng.311","article-title":"Genome-Wide Scan Reveals Association of Psoriasis with IL-23 and NF-\u03baB Pathways","volume":"41","author":"Nair","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/sj.jid.5701255","article-title":"Polymorphisms of the IL12B and IL23R Genes Are Associated with Psoriasis","volume":"128","author":"Nair","year":"2008","journal-title":"J. Investig. Dermatol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Boutet, M.-A., Nerviani, A., Gallo Afflitto, G., and Pitzalis, C. (2018). Role of the IL-23\/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020530"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni.2366","article-title":"IL-12 Family Cytokines: Immunological Playmakers","volume":"13","author":"Vignali","year":"2012","journal-title":"Nat. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2567.2011.03522.x","article-title":"Interleukin-23: As a Drug Target for Autoimmune Inflammatory Diseases","volume":"135","author":"TTang","year":"2012","journal-title":"Immunology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"621956","DOI":"10.3389\/fimmu.2021.621956","article-title":"Major Role of the IL17\/23 Axis in Psoriasis Supports the Development of New Targeted Therapies","volume":"12","author":"Bugaut","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"594735","DOI":"10.3389\/fimmu.2020.594735","article-title":"The IL-23\/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/jdv.14433","article-title":"The Role of IL-23 and the IL-23\/TH 17 Immune Axis in the Pathogenesis and Treatment of Psoriasis","volume":"31","author":"Girolomoni","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Pastor-Fern\u00e1ndez, G., Mariblanca, I.R., and Navarro, M.N. (2020). Decoding IL-23 Signaling Cascade for New Therapeutic Opportunities. Cells, 9.","DOI":"10.3390\/cells9092044"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.0105-2896.2004.00214.x","article-title":"IL-12 and IL-23: Master Regulators of Innate and Adaptive Immunity","volume":"202","author":"Langrish","year":"2004","journal-title":"Immunol. Rev."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2147\/ITT.S240891","article-title":"The Role of IL-17 Cytokines in Psoriasis","volume":"10","author":"Mosca","year":"2021","journal-title":"ImmunoTargets Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","article-title":"The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond","volume":"9","author":"Brembilla","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics Targeting the IL-23 and IL-17 Pathway in Psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"ref_113","first-page":"97","article-title":"Current Developments in the Immunology of Psoriasis","volume":"93","author":"Kerstan","year":"2020","journal-title":"Yale J. Biol. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis Pathogenesis and the Development of Novel Targeted Immune Therapie","volume":"140","author":"Hawkes","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Furue, M., Furue, K., Tsuji, G., and Nakahara, T. (2020). Interleukin-17A and Keratinocytes in Psoriasis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21041275"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3389\/fimmu.2018.01549","article-title":"The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis","volume":"9","author":"Albanesi","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/bjd.15346","article-title":"Noninvasive Proteome Analysis of Psoriatic Stratum Corneum Reflects Pathophysiological Pathways and Is Useful for Drug Profiling","volume":"177","author":"Laffet","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/jid.2009.65","article-title":"Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes in Vitro and in Vivo: Implications for Psoriasis Pathogenesis","volume":"129","author":"Harper","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/JLB.5MR0120-439R","article-title":"Keratinocyte: A Trigger or an Executor of Psoriasis?","volume":"108","author":"Ni","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Jang, D.-I., Lee, A.-H., Shin, H.-Y., Song, H.-R., Park, J.-H., Kang, T.-B., Lee, S.-R., and Yang, S.-H. (2021). The Role of Tumor Necrosis Factor Alpha (TNF-\u03b1) in Autoimmune Disease and Current TNF-\u03b1 Inhibitors in Therapeutics. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052719"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/sj.jidsymp.5650037","article-title":"Mechanisms of Action of Etanercept in Psoriasis","volume":"12","author":"Tan","year":"2007","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3410\/M1-30","article-title":"The Role of TNF Inhibitors in Psoriasis Therapy: New Implications for Associated Comorbidities","volume":"1","author":"Yost","year":"2009","journal-title":"F1000 Med. Rep."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.cyto.2014.12.014","article-title":"Cytokines in Psoriasis","volume":"73","author":"Baliwag","year":"2015","journal-title":"Cytokine"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S1471-4906(01)02005-1","article-title":"IFN-Gamma Production by Antigen-Presenting Cells: Mechanisms Emerge","volume":"22","author":"Frucht","year":"2001","journal-title":"Trends Immunol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"932265","DOI":"10.3389\/fimmu.2022.932265","article-title":"From IL-17 to IFN-\u03b3 in Inflammatory Skin Disorders: Is Transdifferentiation a Potential Treatment Target?","volume":"13","author":"Belpaire","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/cei\/uxac069","article-title":"A Sharp Decrease of Th17, CXCR3+-Th17, and Th17.1 in Peripheral Blood Is Associated with an Early Anti-IL-17-Mediated Clinical Remission in Psoriasis","volume":"210","author":"Tsiogkas","year":"2022","journal-title":"Clin. Exp. Immunol."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Chiricozzi, A., Romanelli, P., Volpe, E., Borsellino, G., and Romanelli, M. (2018). Scanning the Immunopathogenesis of Psoriasis. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010179"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/5584_2020_488","article-title":"Interleukin-36: Structure, Signaling and Function","volume":"21","author":"Zhou","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"108515","DOI":"10.1016\/j.celrep.2020.108515","article-title":"The Proinflammatory Cytokine IL-36\u03b3 Is a Global Discriminator of Harmless Microbes and Invasive Pathogens within Epithelial Tissues","volume":"33","author":"Macleod","year":"2020","journal-title":"Cell Rep."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"155897","DOI":"10.1016\/j.cyto.2022.155897","article-title":"Role of IL-36 Cytokines in Psoriasis and Other Inflammatory Skin Conditions","volume":"156","author":"Sachen","year":"2022","journal-title":"Cytokine"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/jid.2014.532","article-title":"IL-36\u03b3 (IL-1F9) Is a Biomarker for Psoriasis Skin Lesions","volume":"135","author":"Wagenpfeil","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.abd.2021.10.007","article-title":"The Risk of Organ-Based Comorbidities in Psoriasis: A Systematic Review and Meta-Analysis","volume":"97","author":"Tang","year":"2022","journal-title":"An. Bras. Dermatol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"880201","DOI":"10.3389\/fimmu.2022.880201","article-title":"Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review","volume":"13","author":"Bu","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"821","DOI":"10.5603\/KP.2016.0120","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice","volume":"74","author":"Piepoli","year":"2016","journal-title":"Kardiol. Pol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1001\/jamacardio.2017.1213","article-title":"Association Between Skin and Aortic Vascular Inflammation in Patients With Psoriasis: A Case-Cohort Study Using Positron Emission Tomography\/Computed Tomography","volume":"2","author":"Dey","year":"2017","journal-title":"JAMA Cardiol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jaad.2017.06.028","article-title":"The Relationship between Duration of Psoriasis, Vascular Inflammation, and Cardiovascular Events","volume":"77","author":"Egeberg","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1001\/jamadermatol.2016.1984","article-title":"Association Between Changes in Coronary Artery Disease Progression and Treatment With Biologic Agents for Severe Psoriasis","volume":"152","author":"Hjuler","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaad.2016.07.042","article-title":"Cardiovascular Event Risk Assessment in Psoriasis Patients Treated with Tumor Necrosis Factor-\u03b1 Inhibitors versus Methotrexate","volume":"76","author":"Wu","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"868277","DOI":"10.3389\/fimmu.2022.868277","article-title":"Psoriasis and Cardiovascular Diseases: An Immune-Mediated Cross Talk?","volume":"13","author":"Orlando","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/cvr\/cvz009","article-title":"Coronary Artery Plaque Characteristics and Treatment with Biologic Therapy in Severe Psoriasis: Results from a Prospective Observational Study","volume":"115","author":"Elnabawi","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3389\/fimmu.2018.01234","article-title":"Potential Immunological Links Between Psoriasis and Cardiovascular Disease","volume":"9","author":"Sajja","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1070750","DOI":"10.3389\/fimmu.2022.1070750","article-title":"Immunity: Psoriasis Comorbid with Atherosclerosis","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1242\/dmm.001180","article-title":"A Comprehensive Definition for Metabolic Syndrome","volume":"2","author":"Huang","year":"2009","journal-title":"Dis. Model. Mech."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clindermatol.2017.09.005","article-title":"Psoriasis and the Metabolic Syndrome","volume":"36","author":"Gisondi","year":"2018","journal-title":"Clin. Dermatol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/jdv.18044","article-title":"Psoriasis and Metabolic Syndrome: Implications for the Management and Treatment of Psoriasis","volume":"36","author":"Wu","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"711060","DOI":"10.3389\/fimmu.2021.711060","article-title":"Metabolic Syndrome and Psoriasis: Mechanisms and Future Directions","volume":"12","author":"Hao","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1365-2133.2008.08742.x","article-title":"Serum Leptin Levels, Skin Leptin and Leptin Receptor Expression in Psoriasis","volume":"159","author":"Cerman","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Puig, L. (2017). Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010058"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.biopha.2018.02.103","article-title":"The Potential Pathogenic Role of IL-17\/Th17 Cells in Both Type 1 and Type 2 Diabetes Mellitus","volume":"101","author":"Bakery","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/jcb.26174","article-title":"Tumor Necrosis Factor-Alpha: Role in Development of Insulin Resistance and Pathogenesis of Type 2 Diabetes Mellitus","volume":"119","author":"Akash","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ijbiomac.2017.07.155","article-title":"Emerging Role of Interleukins IL-23\/IL-17 Axis and Biochemical Markers in the Pathogenesis of Type 2 Diabetes: Association with Age and Gender in Human Subjects","volume":"105","author":"Fatima","year":"2017","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3389\/fimmu.2015.00308","article-title":"Role of Macrophage Migration Inhibitory Factor in Obesity, Insulin Resistance, Type 2 Diabetes, and Associated Hepatic Co-Morbidities: A Comprehensive Review of Human and Rodent Studies","volume":"6","author":"Morrison","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3389\/fimmu.2018.02262","article-title":"Macrophage Migration Inhibitory Factor (MIF) Drives Murine Psoriasiform Dermatitis","volume":"9","author":"Bezdek","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"20526","DOI":"10.1038\/s41598-022-24872-5","article-title":"The Causal Relationship between Psoriasis, Psoriatic Arthritis, and Inflammatory Bowel Diseases","volume":"12","author":"Sun","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"916645","DOI":"10.3389\/fimmu.2022.916645","article-title":"Causal Association Between Inflammatory Bowel Disease and Psoriasis: A Two-Sample Bidirectional Mendelian Randomization Study","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1159\/000500116","article-title":"Psoriasis and Inflammatory Bowel Disease","volume":"37","author":"Cottone","year":"2019","journal-title":"Dig. Dis."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/ecco-jcc\/jjv110","article-title":"Psoriasis and Inflammatory Bowel Disease: Two Sides of the Same Coin?","volume":"9","author":"Fiorino","year":"2015","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/PTT.S85194","article-title":"Psoriasis and Inflammatory Bowel Disease: Links and Risks","volume":"6","author":"Vlachos","year":"2016","journal-title":"Psoriasis Targets Ther."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical Gastrointestinal Effects of Interleukin-17 Blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/ecco-jcc\/jjw070","article-title":"Similar Depletion of Protective Faecalibacterium Prausnitzii in Psoriasis and Inflammatory Bowel Disease, but Not in Hidradenitis Suppurativa","volume":"10","author":"Eppinga","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"adv00699","DOI":"10.2340\/actadv.v102.1991","article-title":"Sleep Disorders and Psoriasis: An Update","volume":"102","author":"Halioua","year":"2022","journal-title":"Acta Derm.-Venereol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3389\/fendo.2017.00139","article-title":"Psoriasis, Psoriatic Arthritis, and Thyroid Autoimmunity","volume":"8","author":"Ruffilli","year":"2017","journal-title":"Front. Endocrinol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"621072","DOI":"10.1155\/2015\/621072","article-title":"Macrophage Migration Inhibitory Factor Interacting with Th17 Cells May Be Involved in the Pathogenesis of Autoimmune Damage in Hashimoto\u2019s Thyroiditis","volume":"2015","author":"Xue","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"629","DOI":"10.18388\/abp.2008_3023","article-title":"The Role of Nuclear Factor-kappaB in the Development of Autoimmune Diseases: A Link between Genes and Environment","volume":"55","author":"Nauman","year":"2008","journal-title":"Acta Biochim. Pol."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Mleczko, M., Gerkowicz, A., and Krasowska, D. (2022). Chronic Inflammation as the Underlying Mechanism of the Development of Lung Diseases in Psoriasis: A Systematic Review. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031767"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Li, X., Kong, L., Li, F., Chen, C., Xu, R., Wang, H., Peng, S., Zhou, M., and Li, B. (2015). Association between Psoriasis and Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0145221"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1111\/ced.15174","article-title":"Psoriasis and Osteoporosis: A Literature Review","volume":"47","author":"Wi","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s40618-022-01755-0","article-title":"Risk of Non-Alcoholic Fatty Liver Disease in Patients with Chronic Plaque Psoriasis: An Updated Systematic Review and Meta-Analysis of Observational Studies","volume":"45","author":"Bellinato","year":"2022","journal-title":"J. Endocrinol. Investig."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2147\/CCID.S142819","article-title":"Psoriasis and Vitiligo Are Close Relatives","volume":"10","author":"Sharquie","year":"2017","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Zhu, K.-J., Lv, Y.-M., Yin, X.-Y., Wang, Z.-X., Sun, L.-D., He, S.-M., Cheng, H., Hu, D.-Y., Zhang, Z., and Li, Y. (2011). Psoriasis Regression Analysis of MHC Loci Identifies Shared Genetic Variants with Vitiligo. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0023089"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3389\/fmed.2020.00511","article-title":"The Bidirectional Association Between Bullous Pemphigoid and Psoriasis: A Population-Based Cohort Study","volume":"7","author":"Kridin","year":"2020","journal-title":"Front. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/j.jaad.2018.11.036","article-title":"Psoriasis and Hidradenitis Suppurativa: A Large-Scale Population-Based Study","volume":"88","author":"Kridin","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","article-title":"Psoriasis: Which Therapy for Which Patient: Psoriasis Comorbidities and Preferred Systemic Agents","volume":"80","author":"Kaushik","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","article-title":"Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities","volume":"37","author":"Jiang","year":"2023","journal-title":"BioDrugs"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","article-title":"Recategorization of Psoriasis Severity: Delphi Consensus from the International Psoriasis Council","volume":"82","author":"Strober","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/bjd.18333","article-title":"Psoriasis Treat to Target: Defining Outcomes in Psoriasis Using Data from a Real-World, Population-Based Cohort Study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)","volume":"182","author":"Mahil","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/BTT.S252578","article-title":"Biologic Treatments of Psoriasis: An Update for the Clinician","volume":"15","author":"Brownstone","year":"2021","journal-title":"Biol. Targets Ther."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1517\/14712598.2014.896334","article-title":"Etanercept\u2014TNF Receptor and IgG1 Fc Fusion Protein: Is It Different from Other TNF Blockers?","volume":"14","author":"Marotte","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2165\/00003088-200746080-00002","article-title":"Clinical Pharmacokinetics and Use of Infliximab","volume":"46","author":"Klotz","year":"2007","journal-title":"Clin. Pharmacokinet."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Singh, R., Koppu, S., Perche, P.O., and Feldman, S.R. (2021). The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222312793"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2147\/TCRM.S1265","article-title":"Treating Psoriasis with Adalimumab","volume":"4","author":"Alwawi","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4161\/mabs.2.2.11271","article-title":"Certolizumab Pegol","volume":"2","author":"Goel","year":"2010","journal-title":"mAbs"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","article-title":"The Impact of PEGylation on Biological Therapies","volume":"22","author":"Veronese","year":"2008","journal-title":"BioDrugs"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","article-title":"Lack of Placental Transfer of Certolizumab Pegol during Pregnancy: Results from CRIB, a Prospective, Postmarketing, Pharmacokinetic Study","volume":"77","author":"Mariette","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","article-title":"Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review","volume":"22","author":"Yang","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"13466","DOI":"10.1038\/ncomms13466","article-title":"IL-12 Protects from Psoriasiform Skin Inflammation","volume":"7","author":"Kulig","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/bjd.21743","article-title":"Efficacy and Safety of Mirikizumab in Psoriasis: Results from a 52-Week, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Phase III Trial (OASIS-1)","volume":"187","author":"Blauvelt","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1964420","DOI":"10.1080\/19420862.2021.1964420","article-title":"A Non-Clinical Comparative Study of IL-23 Antibodies in Psoriasis","volume":"13","author":"Zhou","year":"2021","journal-title":"mAbs"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"702776","DOI":"10.3389\/fmed.2021.702776","article-title":"A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab","volume":"8","author":"Ghazawi","year":"2021","journal-title":"Front. Med."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"e12946","DOI":"10.1111\/sji.12946","article-title":"The TNF\/IL-23\/IL-17 Axis-Head-to-Head Trials Comparing Different Biologics in Psoriasis Treatment","volume":"92","author":"Petrovic","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"e13403","DOI":"10.1111\/dth.13403","article-title":"Brodalumab: A New Way to Inhibit IL-17 in Psoriasis","volume":"33","author":"Facheris","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/PTT.S367744","article-title":"Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge","volume":"12","author":"Ruggiero","year":"2022","journal-title":"Psoriasis Targets Ther."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/ddr.21263","article-title":"Small Molecules in the Treatment of Psoriasis","volume":"76","author":"Torres","year":"2015","journal-title":"Drug Dev. Res."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00403-020-02056-3","article-title":"Small Molecules under Development for Psoriasis: On the Road to the Individualized Therapies","volume":"312","author":"Claudia","year":"2020","journal-title":"Arch. Dermatol. Res."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2147\/CCID.S266036","article-title":"Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis","volume":"15","author":"Gao","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Caputo, V., Strafella, C., Cosio, T., Lanna, C., Campione, E., Novelli, G., Giardina, E., and Cascella, R. (2021). Pharmacogenomics: An Update on Biologics and Small-Molecule Drugs in the Treatment of Psoriasis. Genes, 12.","DOI":"10.3390\/genes12091398"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/jdv.18812","article-title":"Oral Orismilast: Efficacy and Safety in Moderate-to-Severe Psoriasis and Development of Modified Release Tablets","volume":"37","author":"Warren","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11882-022-01047-w","article-title":"Biologics and Small Molecule Inhibitors: An Update in Therapies for Allergic and Immunologic Skin Diseases","volume":"22","author":"Dodson","year":"2022","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-022-01796-y","article-title":"Deucravacitinib: First Approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.2147\/JIR.S356316","article-title":"Application of Baricitinib in Dermatology","volume":"15","author":"Zhang","year":"2022","journal-title":"J. Inflamm. Res."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"712313","DOI":"10.3389\/fmed.2022.712313","article-title":"Novel Therapeutic Target(s) for Psoriatic Disease","volume":"9","author":"Thakur","year":"2022","journal-title":"Front. Med."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","article-title":"Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Chronic Plaque Psoriasis: Long-Term Efficacy and Safety Results from 2 Randomized Phase-III Studies and 1 Open-Label Long-Term Extension Study","volume":"74","author":"Papp","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s13671-019-0248-y","article-title":"Nanotechnology for Psoriasis Therapy","volume":"8","author":"Murphy","year":"2019","journal-title":"Curr. Dermatol. Rep."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1080\/10717544.2020.1754527","article-title":"Tackling the Various Classes of Nano-Therapeutics Employed in Topical Therapy of Psoriasis","volume":"27","author":"Fereig","year":"2020","journal-title":"Drug Deliv."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"580118","DOI":"10.3389\/fchem.2021.580118","article-title":"Lipid Nanoparticles as Carriers for Bioactive Delivery","volume":"9","author":"Dhiman","year":"2021","journal-title":"Front. Chem."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/s13346-020-00723-6","article-title":"Nanostructured Lipid Carrier Co-Delivering Tacrolimus and TNF-\u03b1 siRNA as an Innovate Approach to Psoriasis","volume":"10","author":"Viegas","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.nano.2017.02.009","article-title":"Nanoemulsion Loaded Gel for Topical Co-Delivery of Clobitasol Propionate and Calcipotriol in Psoriasis","volume":"13","author":"Kaur","year":"2017","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.2217\/nnm.13.202","article-title":"Topical Administration of Dual siRNAs Using Fusogenic Lipid Nanoparticles for Treating Psoriatic-like Plaques","volume":"9","author":"Marepally","year":"2014","journal-title":"Nanomedicine"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejpb.2022.05.012","article-title":"Nanocarriers for the Topical Treatment of Psoriasis\u2014Pathophysiology, Conventional Treatments, Nanotechnology, Regulatory and Toxicology","volume":"176","author":"Carvalho","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.colsurfb.2016.01.021","article-title":"Functionalized Gold Nanoparticles for Topical Delivery of Methotrexate for the Possible Treatment of Psoriasis","volume":"141","author":"Bessar","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.18632\/oncotarget.22260","article-title":"Serum Levels of Adipokines and Cytokines in Psoriasis Patients: A Systematic Review and Meta-Analysis","volume":"9","author":"Bai","year":"2018","journal-title":"Oncotarget"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"705","DOI":"10.5114\/ada.2020.100481","article-title":"Interleukin 22 and 6 Serum Concentrations Decrease under Long-Term Biologic Therapy in Psoriasis","volume":"37","author":"Narbutt","year":"2020","journal-title":"Adv. Dermatol. Allergol."},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Wang, X., Kaiser, H., Kvist-Hansen, A., McCauley, B.D., Skov, L., Hansen, P.R., and Becker, C. (2022). IL-17 Pathway Members as Potential Biomarkers of Effective Systemic Treatment and Cardiovascular Disease in Patients with Moderate-to-Severe Psoriasis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010555"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"s46","DOI":"10.25251\/skin.5.supp.46","article-title":"Mind.Px\u2014Personalized Medicine for Psoriasis Biologic Treatment","volume":"5","author":"Dickerson","year":"2021","journal-title":"SKIN J. Cutan. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/22\/16095\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:19:32Z","timestamp":1760131172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/22\/16095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":214,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["ijms242216095"],"URL":"https:\/\/doi.org\/10.3390\/ijms242216095","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,8]]}}}